NCT05624710View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Renal InsufficiencyKidney Diseases
Interventions
DRUG

INCB054707

INCB054707 75 mg will be administered orally on Day 1.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

78215

Texas Liver Institute Tli the Liver Institute of South Texas List Downtown Office, San Antonio

92780

Orange County Research Center, Tustin

D-81241

Apex Gmbh, Munich

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY